Analyst Coverage

Research reports on Pharmaxis issued by the following organisations are listed below: 

Firm

Analyst

Contact

Bioshares

(initiated coverage: 28 October 2016)

Mark Pachacz (editor)

info@bioshares.com.au

Bell Potter Securities Limited

(initiated coverage: 8 December 2017)

Tanushree Jain (to December 2021)

n/a

Emerald Financial

Emerald Financial

(initiated coverage: 18 May 2021)

Alfred Chan

alfred.chan@principalir.com.au

morgans logo3x

Morgans Financial Limited

Dr Derek Jellinek

Iain Wilkie

Scott Power

derek.jellinek@morgans.com.au

MST Access Services Pty Limited

(initiated coverage: 1 November 2021)

Chris Kallos

Senior Life Science Analyst

 

chris.kallos@mstaccess.com.au

Taylor Collison Ltd

(initiated coverage: 30 November 2021)

Dennis Hulme

dhulme@taylorcollison.com.au
12-April-2022 Following the Science Morgans
08-April-22 PXS-5505 and PXS-6320 R&D Days Taylor Collison
15-Feb-22 Pharmaxis Update Bioshares
31-Jan-22 Making tracks with concurrent trials; 2Q results announced MST Access
6-Dec-21 New capital extends cash runway MST Access
30-Nov-21 Initiation Report: Pharmaxis - Exploring Efficacy in Cancer and Fibrosis Taylor Collison
24-Nov-21 Updated report Emerald
12-Nov-21 New indication for PXS-5505 MST Access
1-Nov-21 Initiation of Coverage MST Access
18-May-21 Initial report Emerald
19-Apr-21 Karst Peak Continues Investment in Austalia Biotech Bioshares
15-Feb-21 Pharmaxis Makes First Commercial Bronchitol Shipment to USA Bioshares
13-Feb-21 1H21 – Result Summary Bell Potter
7-Jan-21 FDA approval for Bronchitol revamps the business, improves outlook Bell Potter
3-Nov-20 Bronchitol FDA Approval a Turning Point for Pharmaxis Bioshares
7-Sep-20 Boehringer Ends Development of Pharmaxis Compound Bioshares
7-Sep-20 BI terminates agreement, discontinues Bell Potter
19-Aug-20 FDA clears IND for myelofibrosis study Bell Potter
13-Aug-20 FY20 Audited Results - No Material Change  Bell Potter
10-Aug-20 A Big Six Months Ahead for Pharmaxis Bioshares
5-Aug-20 Key catalysts expected in Q4CY20 Bell Potter
22-May-20 COVID-19 impacting timing for key catalysts Bell Potter
4-May-20 Pharmaxis - Multiple Assets to Drive Value Bioshares
24-Feb-20 Pharmaxis Remains Confident of Securing LOXL2 Deal Bioshares
13-Feb-20 1H20 Audited Results - No Material Change Bell Potter
6-Feb-20 Down but not out, with turnaround prospects strong in CY20 Bell Potter